查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1365819

傷寒治療市場：依治療類型、給藥途徑、配銷通路：全球機會分析與產業預測，2023-2032

Typhoid Treatment Market By Treatment type, By Route of Administration, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 250 Pages | 商品交期: 2-3個工作天內

價格

2022年傷寒治療市值為29億美元，預計2023年至2032年年複合成長率為5.1%，到2032年將達到48億美元。

傷寒治療市場-IMG1

傷寒是用針對並殺死沙門氏菌的抗生素治療的。常用的抗生素包括氟喹諾酮類、頭孢菌素和阿奇黴素。然而，隨著抗生素抗藥性的上升，治療方法選擇可能會根據區域抗藥性模式和個別患者因素而有所不同。充足的供給、休息和均衡飲食對於恢復期間支持身體非常重要。

傷寒治療市場的成長主要歸因於傷寒感染盛行率的上升。例如，根據美國疾病管制與預防中心（CDC）最新的模型研究，2023年預計全球將出現920萬例傷寒病例、11萬人死亡，其中發病率最高的地區是東南亞。此外，人口成長、都市化和衛生設施的缺乏也會導致感染疾病的傳播，推動市場成長。

目錄

第1章 簡介

第2章 執行摘要

第3章 市場概況

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資機會
  • 波特五力分析
  • 市場動態
    • 促進因素
      • 傷寒流行增加
      • 學名藥抗生素的可得性
      • 活性化研發活動
    • 抑制因素
      • 抗生素抗藥性的發展
      • 核准需要時間
    • 機會
      • 新興市場的成長機會

第4章 傷寒治療市場：依治療類型

  • 概述
  • 抗生素
    • 抗生素傷寒治療市場：依類型
  • 疼痛治療
  • 其他

第5章 傷寒治療市場：依給藥途徑

  • 概述
  • 口服
  • 靜脈注射

第6章 傷寒治療市場：依通路

  • 概述
  • 醫院藥房
  • 藥局和零售藥局
  • 線上提供者

第7章 傷寒治療市場：依地區

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 澳洲
    • 印度
    • 韓國
    • 其他
  • 拉丁美洲、中東、非洲
    • 巴西
    • 沙烏地阿拉伯
    • 南非
    • 其他

第8章 競爭形勢

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭儀表板
  • 競爭熱圖
  • 2022年主要企業定位

第9章 公司簡介

  • Alkem Laboratories Ltd.
  • Lupin
  • Abbott Laboratories
  • SUN PHARMACEUTICAL INDUSTRIES LIMITED
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Limited
  • Cipla Ltd.
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
Product Code: A144387

According to a new report published by Allied Market Research, titled, "Typhoid Treatment Market," The typhoid treatment market was valued at $2.9 billion in 2022, and is estimated to reach $4.8 billion by 2032, growing at a CAGR of 5.1% from 2023 to 2032.

Typhoid Treatment Market - IMG1

The treatment of typhoid involves the use of antibiotics to target and kill the Salmonella bacteria. Commonly prescribed antibiotics include fluoroquinolones, cephalosporins, and azithromycin. However, due to rise in antibiotic resistance, treatment choices may vary based on local resistance patterns and individual patient factors. Adequate hydration, rest, and a balanced diet are essential to support the body during recovery.

The growth of the typhoid treatment market is mainly attributed to a rise in prevalence of typhoid infections. For instance, according to Centers for Disease Control and Prevention (CDC) 2023, updated modeling study estimated 9.2 million typhoid fever cases and 110,000 deaths occurred globally, with the highest estimated incidence in the South-East Asian. In addition, growing population, urbanization, and lack of sanitization factors contribute to the increase in prevalence of typhoid infections. Thereby driving the market growth.

In addition, the increasing trend of global travel and tourism has become a significant contributing factor to the prevalence of typhoid infections, ultimately driving the growth of the typhoid treatment market. As people travel across international borders, they can unknowingly carry the Salmonella typhi bacteria, which causes typhoid fever, from one region to another. This cross-border transmission of the bacteria leads to the spread of typhoid to new areas, where it may not have been prevalent before.

Tourists and travelers often visit destinations with varying levels of hygiene and sanitation standards, including places with limited access to clean drinking water and proper sanitation facilities. In such locations, there is an increased risk of consuming contaminated food and water, which are primary sources of typhoid transmission. In addition, crowded tourist attractions and transportation hubs can facilitate the rapid transmission of the bacteria among travelers.

Moreover, advancements in antibiotic development play a crucial role in driving the growth of the typhoid treatment market. Further, continuous initiatives in R&D for discovery of new oral antibiotics with improved efficacy, expanded spectrum of activity, and reduced side effects drive the market growth. In addition, the growing focus on use of combinational antibiotics for the treatment of resistant typhi bacteria contributes in meeting the unmet medical needs and improve patient outcomes, thereby driving the market growth.

However, the typhoid treatment market faces certain restraints that may impede its growth and development. The emergence and spread of antibiotic resistance pose a significant challenge. Over time, bacteria can develop resistance to the antibiotics, making them less effective in treating infections. This necessitates the development of new antibiotics or alternative treatment options, which can be time-consuming and costly. In addition, stringent regulations and guidelines related to antibiotic use and its prescription contribute to the challenges in the development and market availability of antibiotics for typhoid treatment. This is expected to hinder market growth.

Furthermore, increasing awareness about the importance of timely and appropriate treatment for typhoid infections further drives market growth. Healthcare professionals and public health campaigns emphasizing the appropriate use of antibiotics also contribute to this awareness, thereby boosting the market demand and combating drug resistant typhi infections.

The typhoid treatment market is segmented on the basis of treatment type, route of administration, distribution channel, and region. On the basis of treatment type, the market is classified into antibiotics, pain medication and others. The antibiotics segment is bifurcated into fluoroquinolones, macrolides, cephalosporins, and others. By route of administration; the market is divided into oral and intravenous. Depending on distribution channel, it is categorized into hospital pharmacies, drug stores and retail pharmacies, and online providers. Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).

Major players that operate in the market include Abbott Laboratories, Alkem Laboratories Ltd., Cipla Ltd., Bayer AG, Lupin Limited, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Limited, F. Hoffmann-La Roche Ltd. and Teva Pharmaceutical Industries Limited.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the typhoid treatment market analysis from 2022 to 2032 to identify the prevailing typhoid treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the typhoid treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global typhoid treatment market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)

  • Go To Market Strategy
  • Market share analysis of players by products/segments
  • New Product Development/ Product Matrix of Key Players
  • Average Selling Price Analysis / Price Point Analysis
  • Criss-cross segment analysis- market size and forecast
  • Expanded list for Company Profiles
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)
  • SWOT Analysis

Key Market Segments

By Treatment type

  • Pain Medication
  • Others
  • Antibiotics
    • Type
    • Fluoroquinolones
    • Macrolides
    • Cephalosporins
    • Others

By Route of Administration

  • Oral
  • Intravenous

By Distribution Channel

  • Hospital Pharmacies
  • Drug stores and retail pharmacies
  • Online providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Bayer AG
    • Lupin
    • Cipla Ltd.
    • SUN PHARMACEUTICAL INDUSTRIES LIMITED
    • Alkem Laboratories Ltd.
    • F. Hoffmann-La Roche Ltd.
    • Abbott Laboratories
    • Teva Pharmaceutical Industries Limited
    • Novartis AG
    • Pfizer Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Moderate bargaining power of suppliers
    • 3.3.2. Moderate threat of new entrants
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. Moderate intensity of rivalry
    • 3.3.5. High bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in prevalence of typhoid infectious
      • 3.4.1.2. Availability of generic antibiotics
      • 3.4.1.3. Rise in R&D activities
    • 3.4.2. Restraints
      • 3.4.2.1. Development of antibiotic resistance
      • 3.4.2.2. Time consuming approvals
    • 3.4.3. Opportunities
      • 3.4.3.1. Growth opportunity in emerging markets

CHAPTER 4: TYPHOID TREATMENT MARKET, BY TREATMENT TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Antibiotics
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
    • 4.2.4. Antibiotics Typhoid Treatment Market by Type
  • 4.3. Pain Medication
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Others
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Oral
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Intravenous
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Drug stores and retail pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online providers
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: TYPHOID TREATMENT MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by Treatment type
    • 7.2.3. Market size and forecast, by Route of Administration
    • 7.2.4. Market size and forecast, by Distribution Channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Market size and forecast, by Treatment type
      • 7.2.5.1.2. Market size and forecast, by Route of Administration
      • 7.2.5.1.3. Market size and forecast, by Distribution Channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Market size and forecast, by Treatment type
      • 7.2.5.2.2. Market size and forecast, by Route of Administration
      • 7.2.5.2.3. Market size and forecast, by Distribution Channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Market size and forecast, by Treatment type
      • 7.2.5.3.2. Market size and forecast, by Route of Administration
      • 7.2.5.3.3. Market size and forecast, by Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by Treatment type
    • 7.3.3. Market size and forecast, by Route of Administration
    • 7.3.4. Market size and forecast, by Distribution Channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Market size and forecast, by Treatment type
      • 7.3.5.1.2. Market size and forecast, by Route of Administration
      • 7.3.5.1.3. Market size and forecast, by Distribution Channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Market size and forecast, by Treatment type
      • 7.3.5.2.2. Market size and forecast, by Route of Administration
      • 7.3.5.2.3. Market size and forecast, by Distribution Channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Market size and forecast, by Treatment type
      • 7.3.5.3.2. Market size and forecast, by Route of Administration
      • 7.3.5.3.3. Market size and forecast, by Distribution Channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Market size and forecast, by Treatment type
      • 7.3.5.4.2. Market size and forecast, by Route of Administration
      • 7.3.5.4.3. Market size and forecast, by Distribution Channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Market size and forecast, by Treatment type
      • 7.3.5.5.2. Market size and forecast, by Route of Administration
      • 7.3.5.5.3. Market size and forecast, by Distribution Channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Market size and forecast, by Treatment type
      • 7.3.5.6.2. Market size and forecast, by Route of Administration
      • 7.3.5.6.3. Market size and forecast, by Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by Treatment type
    • 7.4.3. Market size and forecast, by Route of Administration
    • 7.4.4. Market size and forecast, by Distribution Channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Market size and forecast, by Treatment type
      • 7.4.5.1.2. Market size and forecast, by Route of Administration
      • 7.4.5.1.3. Market size and forecast, by Distribution Channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Market size and forecast, by Treatment type
      • 7.4.5.2.2. Market size and forecast, by Route of Administration
      • 7.4.5.2.3. Market size and forecast, by Distribution Channel
      • 7.4.5.3. Australia
      • 7.4.5.3.1. Market size and forecast, by Treatment type
      • 7.4.5.3.2. Market size and forecast, by Route of Administration
      • 7.4.5.3.3. Market size and forecast, by Distribution Channel
      • 7.4.5.4. India
      • 7.4.5.4.1. Market size and forecast, by Treatment type
      • 7.4.5.4.2. Market size and forecast, by Route of Administration
      • 7.4.5.4.3. Market size and forecast, by Distribution Channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Market size and forecast, by Treatment type
      • 7.4.5.5.2. Market size and forecast, by Route of Administration
      • 7.4.5.5.3. Market size and forecast, by Distribution Channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Market size and forecast, by Treatment type
      • 7.4.5.6.2. Market size and forecast, by Route of Administration
      • 7.4.5.6.3. Market size and forecast, by Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast, by Treatment type
    • 7.5.3. Market size and forecast, by Route of Administration
    • 7.5.4. Market size and forecast, by Distribution Channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Market size and forecast, by Treatment type
      • 7.5.5.1.2. Market size and forecast, by Route of Administration
      • 7.5.5.1.3. Market size and forecast, by Distribution Channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Market size and forecast, by Treatment type
      • 7.5.5.2.2. Market size and forecast, by Route of Administration
      • 7.5.5.2.3. Market size and forecast, by Distribution Channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Market size and forecast, by Treatment type
      • 7.5.5.3.2. Market size and forecast, by Route of Administration
      • 7.5.5.3.3. Market size and forecast, by Distribution Channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Market size and forecast, by Treatment type
      • 7.5.5.4.2. Market size and forecast, by Route of Administration
      • 7.5.5.4.3. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Alkem Laboratories Ltd.
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
  • 9.2. Lupin
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. Abbott Laboratories
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
  • 9.4. SUN PHARMACEUTICAL INDUSTRIES LIMITED
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
  • 9.5. Novartis AG
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
    • 9.5.7. Key strategic moves and developments
  • 9.6. Pfizer Inc.
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
  • 9.7. Teva Pharmaceutical Industries Limited
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
    • 9.7.7. Key strategic moves and developments
  • 9.8. Cipla Ltd.
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Bayer AG
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. F. Hoffmann-La Roche Ltd.
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 02. TYPHOID TREATMENT MARKET FOR ANTIBIOTICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. GLOBAL ANTIBIOTICS TYPHOID TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 04. TYPHOID TREATMENT MARKET FOR PAIN MEDICATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. TYPHOID TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. GLOBAL TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 07. TYPHOID TREATMENT MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. TYPHOID TREATMENT MARKET FOR INTRAVENOUS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. GLOBAL TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 10. TYPHOID TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. TYPHOID TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. TYPHOID TREATMENT MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. TYPHOID TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA TYPHOID TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 18. U.S. TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 19. U.S. TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 20. U.S. TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 21. CANADA TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 22. CANADA TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 23. CANADA TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 24. MEXICO TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 26. MEXICO TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 27. EUROPE TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE TYPHOID TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 31. GERMANY TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 32. GERMANY TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 33. GERMANY TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 34. FRANCE TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 36. FRANCE TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 37. UK TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 38. UK TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 39. UK TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 40. ITALY TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 41. ITALY TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 42. ITALY TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 44. SPAIN TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 45. SPAIN TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 46. REST OF EUROPE TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 47. REST OF EUROPE TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 48. REST OF EUROPE TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 49. ASIA-PACIFIC TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 50. ASIA-PACIFIC TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 52. ASIA-PACIFIC TYPHOID TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 53. JAPAN TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 54. JAPAN TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 55. JAPAN TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 56. CHINA TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 57. CHINA TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 58. CHINA TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 59. AUSTRALIA TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 60. AUSTRALIA TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 61. AUSTRALIA TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 62. INDIA TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 63. INDIA TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 64. INDIA TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 65. SOUTH KOREA TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH KOREA TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH KOREA TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 71. LAMEA TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 72. LAMEA TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 73. LAMEA TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 74. LAMEA TYPHOID TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 75. BRAZIL TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 76. BRAZIL TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 77. BRAZIL TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 78. SAUDI ARABIA TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 79. SAUDI ARABIA TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 80. SAUDI ARABIA TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 81. SOUTH AFRICA TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 82. SOUTH AFRICA TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 83. SOUTH AFRICA TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 84. REST OF LAMEA TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 85. REST OF LAMEA TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 86. REST OF LAMEA TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 87. ALKEM LABORATORIES LTD.: KEY EXECUTIVES
  • TABLE 88. ALKEM LABORATORIES LTD.: COMPANY SNAPSHOT
  • TABLE 89. ALKEM LABORATORIES LTD.: PRODUCT SEGMENTS
  • TABLE 90. ALKEM LABORATORIES LTD.: PRODUCT PORTFOLIO
  • TABLE 91. LUPIN: KEY EXECUTIVES
  • TABLE 92. LUPIN: COMPANY SNAPSHOT
  • TABLE 93. LUPIN: PRODUCT SEGMENTS
  • TABLE 94. LUPIN: PRODUCT PORTFOLIO
  • TABLE 95. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 96. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 97. ABBOTT LABORATORIES: PRODUCT SEGMENTS
  • TABLE 98. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 99. SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
  • TABLE 100. SUN PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
  • TABLE 101. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
  • TABLE 102. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 103. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 104. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 105. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 106. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 107. NOVARTIS AG: KEY STRATERGIES
  • TABLE 108. PFIZER INC.: KEY EXECUTIVES
  • TABLE 109. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 110. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 111. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 112. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
  • TABLE 113. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
  • TABLE 114. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
  • TABLE 115. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 116. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES
  • TABLE 117. CIPLA LTD.: KEY EXECUTIVES
  • TABLE 118. CIPLA LTD.: COMPANY SNAPSHOT
  • TABLE 119. CIPLA LTD.: PRODUCT SEGMENTS
  • TABLE 120. CIPLA LTD.: PRODUCT PORTFOLIO
  • TABLE 121. BAYER AG: KEY EXECUTIVES
  • TABLE 122. BAYER AG: COMPANY SNAPSHOT
  • TABLE 123. BAYER AG: PRODUCT SEGMENTS
  • TABLE 124. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 125. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 126. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 127. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
  • TABLE 128. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. TYPHOID TREATMENT MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF TYPHOID TREATMENT MARKET,2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN TYPHOID TREATMENT MARKET (2023-2032)
  • FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 06. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 07. MODERATE INTENSITY OF RIVALRY
  • FIGURE 08. HIGH BARGAINING POWER OF BUYERS
  • FIGURE 09. GLOBAL TYPHOID TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 10. TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022 AND 2032(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF TYPHOID TREATMENT MARKET FOR ANTIBIOTICS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF TYPHOID TREATMENT MARKET FOR PAIN MEDICATION, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF TYPHOID TREATMENT MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF TYPHOID TREATMENT MARKET FOR ORAL, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF TYPHOID TREATMENT MARKET FOR INTRAVENOUS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF TYPHOID TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF TYPHOID TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF TYPHOID TREATMENT MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. TYPHOID TREATMENT MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 22. U.S. TYPHOID TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 23. CANADA TYPHOID TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. MEXICO TYPHOID TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. GERMANY TYPHOID TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. FRANCE TYPHOID TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. UK TYPHOID TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. ITALY TYPHOID TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. SPAIN TYPHOID TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. REST OF EUROPE TYPHOID TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. JAPAN TYPHOID TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. CHINA TYPHOID TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. AUSTRALIA TYPHOID TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. INDIA TYPHOID TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. SOUTH KOREA TYPHOID TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. REST OF ASIA-PACIFIC TYPHOID TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. BRAZIL TYPHOID TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. SAUDI ARABIA TYPHOID TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. SOUTH AFRICA TYPHOID TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. REST OF LAMEA TYPHOID TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. TOP WINNING STRATEGIES, BY YEAR (2020-2022)
  • FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2022)
  • FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY (2020-2022)
  • FIGURE 44. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 45. COMPETITIVE DASHBOARD
  • FIGURE 46. COMPETITIVE HEATMAP: TYPHOID TREATMENT MARKET
  • FIGURE 47. TOP PLAYER POSITIONING, 2022
  • FIGURE 48. ALKEM LABORATORIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 49. ALKEM LABORATORIES LTD.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 50. LUPIN: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 51. LUPIN: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 52. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 53. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 54. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 55. SUN PHARMACEUTICAL INDUSTRIES LIMITED: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 56. SUN PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 57. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 58. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 59. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 60. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 61. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 62. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 63. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 64. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 65. CIPLA LTD.: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 66. CIPLA LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 67. CIPLA LTD.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 68. F. HOFFMANN-LA ROCHE LTD.: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 69. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)